LSI USA Summit Presenting Companies | Emerging Medtech Startups

Joel Krupa

CAO, Agents of Discovery Inc.

Agents of Discovery empowers health and life sciences organizations, cities, universities, airports, sports teams, and other innovation hubs to create place-based learning experiences guided by interactive, AI-powered avatars. Using the Agents platform, teams can support education, workforce training, and community engagement while transforming indoor and outdoor spaces into dynamic, interactive adventures.

Gregory Fischer

Founder & CEO, AiM Medical Robotics

AiM Medical Robotics is a Massachusetts-based neurosurgical robotics company commercializing a compact, MRI-compatible surgical robot that enables intra-operative imaging to account for brain shift and facilitate real-time monitoring of therapy delivery. AiM's platform harnesses real-time MRI to ensure precise placement of neurostimulation leads for Parkinson's patients and its versatile capabilities also support a wide range of neurosurgical procedures, including biopsies, tumor ablation, and intracranial therapeutic delivery with a >$10B market opportunity. Built on over 15 years of NIH-funded research totaling approximately $15 million, AiM's proprietary and patented technology reflects the deep expertise of its founding team that completed an $8.1 million Series A financing round funding a first-in-human clinical trial at Brigham and Women's Hospital in Boston.

Michael Mrochen

Co-Founder & CEO, Allotex

Allotex is pioneering a new category in presbyopia correction with its human collagen corneal inlay. With established commercial traction across Europe, Canada, and other international markets, the company is addressing a large, underserved self-pay market and scaling toward global expansion, supported by strong clinical evidence and a clear regulatory pathway.

Sean Morris

President & CEO, Amplifi Vascular

Amplifi Vascular is developing the Amplifi™ Vein Dilation System, a proprietary blood pump technology designed to enlarge veins and improve outcomes for patients requiring arteriovenous fistula (AVF) surgery. The system is intended to increase AVF eligibility, accelerate maturation, reduce failure rates, and extend primary patency. By addressing key challenges in dialysis access, Amplifi aims to improve treatment outcomes for patients with end-stage renal disease.

Arctx Medical, a clinical-stage medical technology company, is developing the world’s first targeted treatment for Acute Pancreatitis (AP). Local cooling is a well-established therapy for treating acute inflammatory conditions within the body. The Arctx Cool Catheter™ (ACC) Set delivers minimally invasive, localized, and potent cooling therapy to the pancreas, intended to reduce inflammation, accelerate patient recovery, and prevent more serious complications including organ failure and death. Arctx is embarking on an IDE-approved US pivotal clinical trial for this first-ever dedicated treatment for AP. The company has also received FDA marketing authorization for use of the ACC in patient temperature management, a second and mature market for its technology.

Brett Robertson

Director & CEO, ArthroLase

ArthroLase is an Australian medical device company developing an intelligent robotic laser bone shaping system for knee replacement and resurfacing surgery. Its two core platforms, HAiLO and AIRO-x, integrate non-contact high-speed laser bone cutting with surgical robotics, real-time intraoperative 3D digital sensing, and intelligent computer control to achieve sub-millimetre precision in osteotomy procedures.

Souvik Paul

CEO & Founder, Aurie

Aurié

Brad Hauser

CEO, Autonomix Medical, Inc.

Autonomix (Nasdaq: AMIX) is a medical device company developing a minimally invasive nerve-sensing, ablation, and verification system to advance the diagnosis and treatment of diseases involving the nervous system. The company's catheter-based microchip sensing array is designed to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than existing technologies. This platform enables transvascular diagnosis and treatment of conditions affecting the peripheral nervous system. Initially focused on pancreatic cancer pain, Autonomix's technology has potential applications across multiple fields, including cardiology, renal denervation, and chronic pain management.

Meagan Pitcher

CEO & Co-Founder, Bairitone Health

Bairitone is developing an FDA Breakthrough Device-designated diagnostic platform that uses contact acoustic sensing and AI to identify the anatomical site and pattern of airway collapse during natural sleep at home. The platform is intended for clinicians selecting among sleep apnea therapies, including CPAP, oral appliances, surgery, and neurostimulation.

John Brumfield

CEO, Berlin Heals

Berlin Heals is developing the C-MIC system, an implantable electroceutical device that delivers a constant, but minimal, electrical direct current that mimics the physiological electrical currents produced by the heart. The device is a near-curative treatment for patients with heart failure that propagates the reverse remodeling of cardiac muscle tissue to restore heart function and size, thereby reducing the symptoms of heart failure and improving quality of life.

Alexis Peyroles

CEO, BETAGLUE THERAPEUTICS SPA

BetaGlue Therapeutics is a life sciences company that delivers radiotherapy from within. Introducing Yntradose, our proprietary product.

Marcos Sforza

CEO, BMC International Medical

BMC Health is advancing the standard of care in male urology, beginning with urinary incontinence—large, underserved markets constrained by legacy surgical solutions., Its patent-protected platform leverages novel materials and advanced design to replace complex procedures with minimally invasive, office-based therapies. BMC's urinary incontinence system is designed to outperform existing surgical alternatives on safety, simplicity, and clinical adoption. The company is building a broader pipeline across male urologic health and is advancing through global regulatory pathways, led by a team with demonstrated success commercializing implantable medical devices in the U.S. and internationally.

Carrie DiMarzio

CEO, BMI OrganBank

Portable organ testing and preservation device with potential to eliminate the years-long waitlist for lifesaving kidney transplants. We recently received an FDA Breakthrough Device Designation based upon our compelling preclinical data vs. the standard of care.

Alex Herzlinger

CEO, Brandywine MedTech Consultancy

Brandywine MedTech Consultancy specializes in helping innovators commercialize new medical technology.

Lara Zibners

Co-Founder & Chairman, Calla Lily Clinical Care

Calla Lily Clinical Care is a women's health focused company which has developed the proprietary Callavid® platform for intravaginal drug delivery. Initial target indications are in IVF and miscarriage prevention, followed by delivery of live biotherapeutics (LBPs) to reduce antibiotic usage which contributes to antimicrobial resistance (AMR). Further use-cases include effective sample collection to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions.

Mark Alley

CEO, Cipher Surgical

OpClear is an intra operative lens cleaner. The OpClear platform uses automated CO2 flow and on-demand saline lens wash, minimizing the need for scope removal during a procedure and addressing many of the frustrations associated with visual obstructions. This rapidly clears larger visual obstructions such as fogging, misting and blood or particles from energy plumes to provide continuous vision throughout each procedure.

Moises Barbera Ramos

Founder & CEO, CLARO Surgical

CLARO Surgical's platform is an AI-powered surgical guidance system for orthopaedics and trauma, leveraging Mixed Reality to digitize the surgical field and augment it with real-time, X-ray-free navigation. The technology's current platform covers common trauma and orthopedic procedures like intramedullary nailing or plating, reduces drilling and locking time by 86%, improves success rate by 87%, and has already been used to operate on 12 patients successfully.

Regina Atim

CEO & Chief Innovation Officer, Clinicians Touch ALLYVE

Clinicians Touch ALLYVE is developing a wearable maternal bracelet and corresponding application that collects patient-generated data during pregnancy. The device will empower tracking of key data that can be shared with providers to improve outcomes during pregnancy.

Yuval Mandelbaum

CEO, Discure Technologies

Discure Technologies is a stealth-mode startup dedicated to providing relief for millions of people with debilitating back pain. The company is developing a minimally invasive device intended to treat discogenic back pain by reversing degenerative disk disease, a condition associated with over 35% of all low back pain cases. The technology targets the underlying cause of the disease, restoring the disk's healthy function and eliminating pain via a bioelectronic approach.

Kelly Huang

CEO, Elucid

Elucid develops AI software for coronary and carotid CT angiography that quantifies and characterizes atherosclerotic plaque to support personalized cardiovascular care. Its FDA-cleared Plaque-IQ™ software provides patient-specific plaque analysis, and the company is pursuing FDA-clearance of its BioIntegrated FFR-CT technology derived from the same plaque input to enable integrated anatomic and functional assessment of coronary artery disease.

Greg Parranto

CEO, Endeavor Orthopaedics

Endeavor Orthopaedics is an IP-protected platform technology company focused on the integration of fracture repair with soft tissue management of deforming forces. The combination of plate/screw and suture construct in one implant allows surgeons to address not only the osseous fracture repair but also the soft-tissue deforming forces, creating a bio-mechanical advantage during patient recovery.

Alan Lucas

CEO & Co-Founder, enlightenVue

enlightenVue is a development stage company producing an advanced suite of single-use micro-endoscopes. Our endoscopes directly address the high risk of exposure to potentially deadly bacteria from contaminated medical instruments during endoscopic procedures. The underlying problem is the difficulty and expense of current endoscope systems that require reprocessing and sterilization between patients, keeping the procedures primarily restricted to the hospital or outpatient clinical environment. Despite the small size, our micro-endoscopes offer two functioning working channel, light source and a High Definition camera within the body of the endoscope.

Field Medical, Inc. was founded by Dr. Steven Mickelsen to realize the second generation pulsed field ablation therapy system for treatmet of broad heart arrhythmia conditions.

Jennifer Fried

Co-Founder & CEO, Flow Medical

Flow Medical is developing a catheter-directed thrombolysis platform for the treatment of intermediate-risk pulmonary embolism. The device combines thrombolytic drug delivery with continuous pulmonary artery pressure monitoring, enabling real-time assessment of a patient's hemodynamic response during therapy.

John Wong

CEO, Fluid Biomed

Fluid Biomed is developing the world's first bioabsorbable neurovascular stent to cure brain aneurysms

Laura Becerra-Fajardo

CEO, FORESEE MedTech

FORESEE MedTech is a deep-tech spin-off awardee of the European Innovation Council (EIC) Transition grant (2.5 M€), that is developing an intravascular multiparametric sensing platform for remote monitoring of chronic conditions, starting with heart failure. FORESEE's solution aims to support earlier interventions, reduce hospitalizations, empower patients and improve long-term outcomes in this cardiovascular condition. Thanks to the ability to measure multiple parameters from a single intravascular device, FORESEE will improve patient management by addressing the fact that in heart failure "one size does not fit all

Bruce Batten

Founder/CSO, GRIP Molecular Technologies, Inc.

GRIP Molecular Technologies has developed a novel CRISPR-based diagnostic that enables molecular testing in a simple lateral flow format for both point-of-care (POC) and point-of-need (PON) infectious disease testing. The platform delivers test results comparable to existing POC and lab-based molecular tests in under 15 minutes at room temperature, eliminating the need for specialized equipment or laboratory infrastructure. This breakthrough technology positions GRIP to address the growing demand for rapid, accurate, and accessible molecular diagnostics in diverse healthcare settings.

Raj Shah

CEO, GuideAI Health

GuideAI Health automates the early detection of chronic vascular disease in CT scans through advanced AI models developed by clinicians and AI/ML experts. The platform's first product addresses the 90% underdiagnosis/misdiagnosis rate of peripheral vascular disease in current practice by rapidly identifying and reporting subtle disease markers, enabling early intervention before life altering complications develop through disease-to-treatment precision.

Christopher Lee

Co-Founder & CEO, HapticHeart Solutions

HapticHeart Solutions is advancing a wearable haptic feedback platform—featuring a glove and armband—that restores tactile sensation in catheter-based, minimally invasive, and robotic procedures. By converting physical and physiological signals into real-time touch and force feedback, the system aims to enhance surgical precision, shorten learning curves, and improve patient outcomes. Currently at Technology Readiness Level 6, the prototype has demonstrated clinical utility in electrophysiology and is being expanded for use in robotic surgery.

Mike Connolly

CEO, Healionics

Healionics is developing safer, more reliable means of bloodstream access to support life-saving dialysis therapy in kidney failure patients. Its FDA Breakthrough-designated STARgraft AV graft has 24-month clinical results that show outstanding resistance to both occlusion and infection — the two primary causes of failure in on-market grafts. The company also has a diverse product pipeline leveraging its core STAR biomaterial technology which can inhibit scar tissue encapsulation and infection to improve the performance of a wide range of other implantable devices and facilitate creation of entirely novel ones.

Francis White

CEO, Heart Biotech Holdings

The Yacoub Heart Valve: A unique, tissue-engineered valve that promises to revolutionise heart valve replacement with no compromises. Using intricate scaffold technology that transforms in-situ into a living heart valve, using the body's own healing processes to regenerate as nature intended. Restoring full life expectancy and in kids, adapting and growing.

Scott Klein

CEO, HelpWear

HelpWear is striving to better at-home healthcare by developing affordable and accessible products for patients all around the world. HelpWear is currently developing its first product, the HeartWatch, allowing for 24/7 at home heart monitoring with an embedded emergency contact system for furthered prevention and bettered treatment of heart related illness.

Adam Clark

CEO, IMRA Surgical

Advanced training for surgeons to enhance the use of minimally invasive robotics in surgery and improve patient outcomes.

Imanuel Lerman

CEO & Founder, InflammaSense

InflammaSense is a medical technology company pioneering a first-of-its-kind AI-driven sepsis monitoring platform that combines Autonomic Neurography (ANG) and micro-RNA profiling to continuously track the body's inflammatory signals in real time. This unique platform detects organ-specific infection signals and triggers precise micro-RNA biomarker tests, providing real-time insights that guide tailored treatment decisions for sepsis. By enabling faster sepsis diagnosis, precision therapy guidance, and significant hospital cost savings through shorter hospital stays, InflammaSense delivers improved patient outcomes and a compelling value proposition for healthcare systems.

Peter Fischer

CEO, Inkspace Imaging

InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics.

Rubén Molina

CEO & Co-Founder, INNITIUS

Innitius has developed a quantitative diagnostic platform that measures cervical tissue biomechanics combined with AI models to support clinical decision-making in obstetrics. The technology addresses key use cases including threatened preterm labor, early preterm birth risk stratification, and induction of labor, enabling more accurate and objective assessment at the point of care.

Harlee Sorkin

CEO, InterShunt

InterShunt is developing a minimally invasive catheter therapy for heart failure, the leading cause of hospitalization and Medicare expense. Currently in clinical phase, the procedure dynamically offloads left atrial pressure, addressing the most debilitating symptoms in patients with limited treatment options.

Jeff Chandler

Co-founder, President & CEO, KiriGenX Inc.

KiriGenX is developing the first bioinductive collagen implant platform purpose-built for early-stage rotator cuff disease at the articular side. The technology delivers a biologic scaffold to support tendon healing in an underserved patient population and is advancing through a 510(k) pathway, with planned expansion into broader tendon repair indications.

Liquet Medical is developing catheter-based technology for the treatment of pulmonary embolism (PE). Our Versus™ Catheter combines bilateral pulmonary artery drug delivery with continuous, real-time pulmonary artery pressure monitoring through a single venous access, enabling physicians to assess hemodynamic response during catheter-directed thrombolysis.

Colby Holtshouse

CEO, May Health

May Health is developing a minimally invasive treatment for polycystic ovary syndrome (PCOS), a leading cause of female infertility due to ovulatory dysfunction. Current treatment options—including drug therapy, surgical ovarian drilling, and IVF—carry risks such as multiple pregnancies, invasiveness, and high costs. May Health's approach aims to replicate the effectiveness of ovarian drilling while reducing procedural risk and invasiveness. The goal is to enable more natural conception pathways for women with PCOS.

Alex Joseph

Commercial Lead, Microsure

Microsure develops MUSA-3, a CE-marked robotic system for open microsurgery and supermicrosurgery. The system scales and tremor-filters the surgeon's hand movements and works with standard microsurgical instruments, enabling procedures on vessels under one millimetre, such as lymphatic reconstruction for lymphedema.

Nico Fenu

Co-founder & CEO, Nami Surgical

Nami Surgical has developed the world's first miniaturized ultrasonic scalpel designed specifically for robotic-assisted surgery and the only ultrasonic technology engineered to articulate through wristed robotic joints. This represents a major unmet need in robotic surgery, where ultrasonic energy solutions remain constrained by size, articulation, and integration limitations.

Ben Holmes

CEO, NANOCHON

Nanochon's Chondrograft™ is a synthetic, off-the-shelf implant designed to treat focal chondral and osteochondral knee defects in active patients. Made from a proprietary polymer blend and 3D-printed to mimic natural cartilage and bone architecture, it provides immediate mechanical support while promoting long-term tissue regeneration—bridging the gap between conservative care and total knee replacement.

Dr. Chinelo Nwaogbo, DNP, APRN, FNP-C, CWS

Founder & CEO, NELO

NELO Smart Sharps System is an intelligent enclosure that retrofits existing sharps containers to help prevent overfilling and reduce needlestick injury risk. The system combines real-time fill-level monitoring, visual status indicators, automatic locking at capacity, and compliance tracking to improve safety and support OSHA-aligned sharps management across healthcare facilities.

George Kramer

CEO, Neocor

NeoCor develops the CoApt Valve®, a transcatheter device designed to treat severe mitral and tricuspid valve disease through a minimally invasive approach. The CoApt Valve features a self-expanding nitinol frame and an electrospun polymeric valve, aiming to reduce or eliminate regurgitant jets without the need for open-heart surgery. The device is delivered via a catheter inserted through the transfemoral vein, preserving the native valve structure. CoApt Valve is advancing its technology through preclinical studies in both canine and human models, with plans to initiate veterinary clinical trials.

Manfred Franke

CEO, Neuronoff, Inc.

The Injectrode® Platform aims to provide chronic pain patients with an easy way to get relief without drugs or invasive surgeries.

Oliver Piepenstock

CEO & Founder, Noah Labs

Noah Labs Vox eliminates the no. 1 cause of hospital admissions - congestive heart failure - 3 weeks before hospitalization by analyzing voice changes caused by fluid build-up in the lungs and vocal tract. Trained on the world's largest heart failure voice data set, the patented technology is being piloted at Mayo Clinic, UCSF and Charité Berlin.

Barry McCann

Founder & CEO, NUA Surgical

NUA Surgical® is an award-winning Irish MedTech company innovating in Women's Health. Developed out of BioInnovate Ireland and the University of Galway, we've patented the SteriCISION® C-Section Retractor — a single-use, self-retaining retractor improving access and outcomes during Caesarean delivery. Founded in 2018, we're now VC-backed, having closed a €6.5M Series A in December 2024 led by EQT Life Sciences, with Kidron Capital, Texas Medical Center Venture Fund and Enterprise Ireland participating. We're using this to drive regulatory clearance and commercialisation across Europe and the US.

Kath Giles

Managing Director & CEO, OncoRes Medical

OncoRes Medical is a clinical stage company developing a novel imaging modality (QME) that generates microscale maps of tissue stiffness, enabling identification of residual cancer inside the surgical cavity and complete tumour clearance. This advanced imaging technology, focused on breast cancer conserving surgery first, is broadly applicable across the 17 million solid tumours diagnosed globally and can be incorporated into minimally invasive and robotic surgical tools.

Laura Yecies

CEO, Osteoboost Health

Osteoboost is the first and only FDA-cleared wearable therapy for osteopenia—clinically proven to reduce bone loss in the spine. Order online with prescription.

Conner Herman

CEO, Percy

Percy is a paradigm-shifting contactless, non-video, multi-sensor behavioral sleep monitoring device with thermal, radar, microphones, and environmental sensors and an AI algorithm that intuits behavioral insights in real time. Doctors access a database where they can access a timeline with objective baseline data to identify episodic problematic events that disrupt sleep, discriminate between medical and behavioral sleep challenges, and monitor treatment compliance without patient report.

Patrick Anquetil

CEO, Portal Instruments, Inc.

Biologics grow in volume and viscosity, pharma companies are pushing to move therapies from infusion to at-home subcutaneous delivery, exposing the limits of traditional spring-based injectors. Portal Instruments is developing software-defined, computer-controlled auto-injectors that actively regulate pressure and flow to enable reliable large-volume delivery across viscosities while supporting a broader range of formulations. By capturing real-time injection data, the NEXUS platform can support adherence and therapy management and serve as a cornerstone for future AI-enabled therapies, positioning drug delivery as both a device and data platform.

Joanna Nathan

CEO & Co-Founder, Prana Surgical

A minimally invasive, lung-sparing device that will provide physicians and patients with the certainty they need to move forward with treatment.

David Carey

CEO, Preceptis Medical

Preceptis Medical develops technologies that enable pediatric ear tube procedures to be performed in the office without general anesthesia. The Hummingbird® Tympanostomy Tube System (TTS) allows ENTs to place ear tubes efficiently under local anesthesia, eliminating the need for an operating room while maintaining established standards of safety and effectiveness for one of the most common pediatric procedures.

Chris Lear

Chief Strategy Officer, Prometheus Therapeutics

Prometheus Therapeutics has developed the world's first Regenerative Photobiomodulation (PBM) platform to stimulate biologic healing. This is a patent-protected technology platform, and our first mission addresses the most significant unresolved clinical issue in Brain Aneurysm Care: awful long-term occlusion rates.

Carl Daintree

CEO, QV Bioelectronics

QV Bioelectronics is developing GRACE, an implantable Tumour Treating Fields (TTF) device platform for treating solid tumours, initially focusing on glioblastoma (GBM). Placed during tumour resection surgery, GRACE delivers targeted TTF from within the body to disrupt cancer cell division, with an implantable design intended to maximise patient quality of life.

Daniel Walzman

Founder & CEO, Radial1

Radial1 has developed unique endovascular catheter technologies for Neurovascular, Cardiovascular and Peripheral Vascular applications. Full line of stroke aspiration catheters feature the lowest profiles and LARGEST LUMENS in the world. Largest lumen Guide catheters, lowest profile Radial-to-peripheral and Radial-to-brain sheaths, lowest profile diagnostic catheters, and lowest profile access sheaths. Groundbreaking steerable technologies as well. Raising Series A

Michael Nagel

CEO, Raydiant Oximetry

Raydiant Oximetry is a privately held, clinical stage medical technology company aimed at elevating the standard of care for labor and delivery with two fetal pulse oximetry technologies. Leveraging advanced biophotonics and machine learning, fetal pulse oximetry has the potential to reduce risks associated with emergency c-sections and hypoxic events during childbirth. The technology is also compatible with existing monitor platforms, clinical workflows and reimbursement codes.

Justin Sutherland

CEO, Realize Medical

Realize Medical makes patient-specific planning easy with, FDA-cleared Elucis, the world's first all-in-one VR-based medical modeling and collaboration platform. Elucis is a mixed reality software platform for surgical planning that transforms medical images into interactive 3D models. It enables clinicians to visualize, design, and plan complex procedures with precision and collaboration, improving understanding, communication, and patient outcomes.

Mark Pacyna

CEO, Reprieve Cardiovascular

Reprieve Cardiovascular is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients.

Marc Zemel

CEO, Retia Medical

Retia develops healthtech AI algorithms for helping guide management of surgical and critically ill patients to improve outcomes. This is a $4 billion market. The company's technology has been clinically validated and is used in 65 hospitals.

Olivier Delporte

CEO, SamanTree Medical

SamanTree Medical's Histolog Scanner is a digital microscopy scanner for high-resolution imaging of the surface of fresh tissue. The device utilizes novel, ultra-fast confocal microscopy technology to enable rapid histological assessment in the operating room or pathology laboratory.

Maria Artunduaga

CEO, Samay

Samay's Sylvee is the first wearable to match CT performance, the gold standard, for early COPD detection, identifying small airway disease up to 5 years before spirometry can detect any changes. Validated in 450+ patients (AUC 0.93) and protected by 18 patents across 20+ countries, Samay is already generating revenue with a top European respiratory pharma, a world-leading sleep company, and a top US academic medical center, while preparing for a late 2027 launch across 1,500 clinics through Latam's third-largest payer and investor.

Bart Bandy

CEO, Solenic Medical

Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hip replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants.

Anders Sideris

CEO & Co-Founder, Somnair

Somnair is a first-in-class, non-invasive neurostimulation oral appliance for the treatment of obstructive sleep apnea. The custom-fitted device stimulates a novel neuroanatomical target to maintain airway patency during sleep. Somnair's technology is designed for convenient at-home use.

Jim Fidacaro

CEO, Sonion Health

Sonion Health is dedicated to revolutionizing hypertension care through our cutting-edge optical biosensing technology and artificial intelligence, enabling a cuffless wearable device that provides continuous access to clinical-grade blood pressure monitoring. This device offers real-time, precise readings throughout daily activities—including sitting, semi-fowler, and supine—setting new benchmarks in hypertension diagnosis, remote patient monitoring (RPM), and inpatient care.

Dimitri Sokolov

CEO, Spiro Robotics

Spiro Robotics is developing an innovative handheld robot intended to automate airway management in patients requiring tracheal intubation.

Amir Soltanianzadeh

CEO, StimCardio Medical

StimCardio Medical (formerly CardiaCare) is a medical device company developing a non-invasive, wearable neuromodulation platform designed to support patients with atrial fibrillation. The StimCardio system integrates continuous physiological monitoring, advanced signal analysis, and personalized peripheral neuromodulation with the goal of restoring autonomic balance and improving heart–brain communication. StimCardio is advancing a patient-centric, home-based approach to arrhythmia management that complements existing clinical care pathways.

Justin Anderson

Chief Executive Officer, President, and Chairman, Tensor Surgical

Tensor Surgical develops technologies for orthopedic soft tissue repair sports medicine. The company's portfolio of products consists of solutions to simplify and reduce the cost rotator cuff repair and bicep tenodesis procedures.

Rob Krummen

CEO, Vektor Medical, Inc.

Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency.

Adam Gridley

CEO, Vergent Bioscience

Vergent's lead compound, abenacianine for injection (VGT-309), is a next generation tumor-targeted fluorescent imaging agent for cancer surgery designed to provide real-time, intraoperative visual and molecular feedback on tumor location and help surgeons ensure all tumor tissue is removed during minimally invasive surgery (MIS) procedures. Abenacianine is designed to be an ideal targeted imaging agent and is compatible across NIR enabled surgical visualization platforms, works across all solid tumor types, and has a differentiated mechanism of action that allows for a wide dosing window to seamlessly fit into surgery workflows.

John Santini

Chief Technology Officer, Vergent Bioscience

Vergent’s lead compound, abenacianine for injection (VGT-309), is a next generation tumor-targeted fluorescent imaging agent for cancer surgery designed to provide real-time, intraoperative visual and molecular feedback on tumor location and help surgeons ensure all tumor tissue is removed during minimally invasive surgery (MIS) procedures. Abenacianine is designed to be an ideal targeted imaging agent and is compatible across NIR enabled surgical visualization platforms, works across all solid tumor types, and has a differentiated mechanism of action that allows for a wide dosing window to seamlessly fit into surgery workflows.

Finbar Dolan

CEO, VERSONO Medical

Versono is developing an intravascular ultrasonic platform to improve the crossing of severe occlusions in the peripheral vasculature. The device will prepare a working lumen to support endovascular therapy in patients with chronic total occlusions (CTOs) and critical limb ischemia (CLI).

Lakshmi Dasi

Co-Founder & CTO, YoungHeartValve

YoungHeartValve is developing a fully synthetic, polymer-based transcatheter aortic valve designed to deliver lifelong durability without the need for chronic anticoagulation. The company is advancing its transcatheter aortic valve platform to address one of structural heart's most persistent trade-offs: durability versus safety. The system is currently in the advanced preclinical stage, with ongoing chronic large-animal studies and a latest design that has met regulatory bench-testing requirements for valve performance and mechanical durability. The team has implemented a soft design freeze incorporating physician feedback from earlier acute implantations to optimize both hemodynamic performance and procedural usability.